Microalbuminuria
Microalbuminuria
复制标题
DOI：
10.1081/ceh-200031985
复制
发表时间：
2004-10-01
影响因子：
12.3
通讯作者：
Rodicio, JL
中科院分区：
文献类型：
--
作者：
Segura, J;Ruilope, LM;Rodicio, JL
微量白蛋白尿预测心血管和肾脏风险增加的能力在糖尿病患者、高血压患者和普通人群中都得到了很好的证实。因此，微量白蛋白尿的检测可能有助于选择特定的治疗策略，以减少或预防高血压患者的心血管事件。在确诊高血压的人群中，几乎40%的人可以检测到微量白蛋白尿，特别是那些通过药物治疗没有得到满意控制的患者。蛋白尿可能是高血压病患者肾脏损害和心血管风险的标志。微量白蛋白尿似乎是一种简单和可重复的方法，可以更好地确定高血压患者的心血管风险概况，并根据肾脏和心血管风险对预后进行分层。血管紧张素转换酶抑制剂和最近的血管紧张素11受体拮抗剂似乎显示出更大的市场容量来减少高血压或糖尿病患者的微量蛋白尿。在日常临床实践中确定这一参数有助于高血压患者的风险分层和治疗选择。
The capacity of microalbuminuria to predict an increased cardiovascular and renal risk is well established in diabetic patients, as well as in essential hypertensive patients and in general population. Detection of microalbuminuria could then be relevant to select specific therapeutic strategies for reducing or preventing cardiovascular events in patients with essential hypertension. Microalbuminuria is detectable in almost 40% of the population with established hypertension, particularly in those patients not controlled satisfactorily with medical therapy. Albuminuria may represent a marker of renal damage and cardiovascular risk in essential hypertension. Microalbuminuria seems to represent a simple and reproducible method to better define cardiovascular risk profile in the hypertensive patient and to stratify the prognosis in relation to renal and cardiovascular risk. ACE-inhibitors and more recently angiotensin 11 receptor antagonists seem to exhibit a more market capacity to reduce microalbuminuria in patients with essential hypertension or diabetes mellitus. Determination of this parameter in daily clinical practice could facilitate the stratification of risk as well as the choice of therapy in essential hypertensive patients.